Ganitumab (AMG 479) is a highly potent monoclonal antibody to type 1 insulin-like growth factor receptor (IGF1R). Ganitumab is recognized to bind to IGF1R at low concentration with KD value of 0.22 nM. Ganitumab can inhibit the interaction of IGF1R with IGF1 and IGF2 in mice. Ganitumab can be used to study cancer.